Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) reports positive CAN10 results
Published by Arron Aatkar

Cantargia has reported that all nine groups involved in its Phase I CAN10 programme, including 68 participants receiving a single dose of CAN10 or placebo, have demonstrated encouraging biomarker results and showed desirable responses in terms of safety. Furthermore, it was found that even one week post infusion, a single dose of CAN10 completely inhibited IL-1 signalling. Combined with prior results confirming blockade of IL-36 stimulation, the endpoints for the trial have been reached. Cantargia is now focused on completing the second part of this trial, assessing multiple dosing.

Beyond this, the first Phase II trial for CAN10 is anticipated to commence in H225, aiming to evaluate the candidate in autoimmune/inflammatory diseases, potentially including hidradenitis suppurativa or systemic sclerosis.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free